A long-term survival case of unresectable gastric cancer with multidisciplinary therapy including immunotherapy and abscopal effect-Reference-Cited by-同舟云学术

A long-term survival case of unresectable gastric cancer with multidisciplinary therapy including immunotherapy and abscopal effect

Published:2020-07-24 Issue:4 Volume:9 Page:193-198
ISSN:2192-3183
Container-title:International Cancer Conference Journal
language:en
Short-container-title:Int Canc Conf J

Author:

Kuhara Yuta^ORCID,Ninomiya Motoki,Hirahara Satoshi,Doi Hirofumi,Kenji Shirakawa,Toyota Kazuhiro,Yano Raita,Kobayashi Hironori,Hashimoto Yasushi,Yokoyama Yujiro,Sakashita Yoshihiro,Miyamoto Katsunari

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s13691-020-00433-3.pdf

Reference22 articles.

1. Ohtsu A, Shimada Y, Shirao K et al (2003) Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 21:54–59

2. Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet 376:687–697

3. Weber JS, D'Angelo SP, Minor D et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomized, controlled, open-label, phase 3 trial. Lancet Oncol 16:375–384

4. Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123–135

5. Kang YK, Boku N, Satoh T et al (2017) Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet 390:2461–2471

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathological Complete Response Achieved with XELOX Chemotherapy, HIPEC, and Anti-PD-1 Immunotherapy in Stage IV Gastric Adenocarcinoma with Peritoneal Metastasis: A Case Report and Review of the Literature;Journal of Gastrointestinal Cancer;2024-04-27

2. Molecular Classifications in Gastric Cancer: A Call for Interdisciplinary Collaboration;International Journal of Molecular Sciences;2024-02-24

3. Regional Immunotherapy for Peritoneal Carcinomatosis in Gastroesophageal Cancer: Emerging Strategies to Re-Condition a Maladaptive Tumor Environment;Cancers;2023-10-23

4. Pathological complete response with nivolumab for recurrence of liver metastasis after gastrectomy of gastric cancer;Surgical Case Reports;2023-05-19

5. Abscopal Effect on Bone Metastases from Solid Tumors: A Systematic Review and Retrospective Analysis of Challenge within a Challenge;Biomedicines;2023-04-12